Shortening Tuberculosis Treatment with Fluoroquinolones: Lost in Translation?

Research output: Contribution to journalReview article

Abstract

The disappointing recent failure of fluoroquinolone-containing regimens to shorten the duration of tuberculosis treatment in costly phase 3 trials has raised serious questions about the reliability of preclinical tuberculosis models, especially mice, and the current paradigm of regimen development. Therefore we re-examined data from murine models and early-stage clinical trials on which the pivotal trials were based, concluding that phase 3 trial results were in line with preceding studies. Finally, we offer suggestions for a more efficient and integrated preclinical and clinical regimen development program where quantitative pharmacokinetic and pharmacodynamic models more predictive of curative treatment durations are set forth.

Original languageEnglish (US)
Pages (from-to)484-490
Number of pages7
JournalClinical Infectious Diseases
Volume62
Issue number4
DOIs
StatePublished - Nov 4 2015

    Fingerprint

Keywords

  • OFLOTUB
  • REMox-TB
  • fluoroquinolones
  • shortening regimen
  • tuberculosis

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this